A5024437430- Herpesvirus Infections and Treatments
- Acne and Rosacea Treatments and Effects
- Pharmaceutical Practices and Patient Outcomes
- Cytomegalovirus and herpesvirus research
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Innovations in Medical Education
- Hepatitis Viruses Studies and Epidemiology
- Hepatitis B Virus Studies
- Bartonella species infections research
- COVID-19 and healthcare impacts
- Vector-borne infectious diseases
- Medication Adherence and Compliance
- COVID-19 Clinical Research Studies
- Chronic Disease Management Strategies
- Systemic Lupus Erythematosus Research
- Rabies epidemiology and control
- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Interprofessional Education and Collaboration
- Pharmacy and Medical Practices
- Perfectionism, Procrastination, Anxiety Studies
- Primary Care and Health Outcomes
- Healthcare Systems and Reforms
- Patient Satisfaction in Healthcare
GlaxoSmithKline (United States)
2016-2023
St George’s University Hospitals NHS Foundation Trust
2023
Janssen (United States)
2021-2022
Health Outcomes Solutions (United States)
2021
Kaiser Permanente
2020
Truven Health Analytics (United States)
2018
University of the Sciences
2014-2017
Ball State University
2017
University of Iowa
2010-2014
The University of Texas at Austin
2007-2008
Data on the epidemiology of herpes zoster (HZ), particularly in unvaccinated immunocompetent population, are needed to assess disease burden and potential impact vaccination.The study at a large health care organization comprised: (1) incidence estimated from adults aged ≥50 years with vaccine live who had incident HZ 2011-2015; (2) proportion HZ-related nonpain complications assessed by double abstraction electronic records (EHRs) 600 patients (3) hospitalizations among diagnosed 2015; (4)...
Pharmacists in the United States (U.S.) are authorized to administer vaccines. This study described: how and what extent immunization services offered, promoted, documented community pharmacies; reasons for referral other locations vaccination; perceived barriers services.A mixed-mode (mail/electronic) survey of a stratified random sample 1999 nationally-representative pharmacies U.S. was conducted April-July 2017. Survey instrument development informed by validated scales 10 in-depth...
In the United States, herpes zoster (HZ) and related complications are estimated to result in approximately $1.3 billion medical care costs $1.7 indirect annually. this study, we compared cost-effectiveness of a new Adjuvanted Recombinant Zoster Vaccine (RZV), containing recombinant varicella-zoster virus glycoprotein E AS01B Adjuvant System, versus No Vaccine, as well live attenuated HZ vaccine (Zoster Live (ZVL)) subjects aged 60+ years age (YOA) other cohorts 50+ YOA. A multi-cohort...
Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant (RZV) was approved 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccination with RZV immunocompetent adults aged 50+ years old, including those previously vaccinated ZVL. objective this study to determine cost-effectiveness vaccinating 60+ ZOster ecoNomic Analysis (ZONA) model,...
Herpes zoster (HZ) incidence increases with age, and the burden of HZ is expected to grow aging populations worldwide. We aim determine incremental healthcare resource utilization associated costs patients common HZ-related complications other than postherpetic neuralgia (cutaneous, neurologic ophthalmic) compared uncomplicated HZ. conducted a retrospective cohort study commercial health insurance claims covering about 40 million immunocompetent individuals aged ≥50 years at entry from all...
Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 the United States (US) for prevention of herpes adults aged 50 years and older. The vaccine is administered two doses, with second dose administration recommended between six months after first dose. Examination uptake series completion important to ensure appropriate use, especially at time introduction. This report provides demographic characteristics patients receiving RZV September 2019, first- second-dose uptake, a...
Individuals who are immunocompromised (IC) due to therapy or underlying disease at increased risk of herpes zoster (HZ). This study evaluates the public health impact recombinant vaccine (RZV) relative no HZ vaccination for prevention among adults aged ≥18 years diagnosed with selected cancers in United States (US). A static Markov model was used simulate three cohorts individuals IC cancer (time horizon 30 years; one-year cycle length): hematopoietic stem cell transplant (HSCT) recipients,...
To estimate the risk of transient ischemic attack (TIA), stroke, and myocardial infarction in periods covering 4 weeks before to 52 after herpes zoster (HZ) diagnosis US adults.This retrospective study (GSK identifier: HO-15-15771) with matched cohorts used Truven Health MarketScan Commercial Medicare claims data set linked obesity smoking status information. Patients 18 years older at date HZ 1-year pre- post-HZ continuous insurance enrollment (from January 1, 2007, through December 31,...
To examine pharmacy-based influenza vaccination using diffusion of innovation theory.We used 1993 to 2013 Behavioral Risk Factor Surveillance System data generate weighted prevalence rates vaccination, stratified by age (18-64 years vs ≥ 65 years) and state residence. The theory adopter categories were residents states allowing pharmacist before 1996 ("innovator/early adopters"), between 1998 ("early majority"), 1999 2004 ("late in 2007 or later ("laggards").For adults aged 18 64 years,...
Hepatitis A and B disease burden persists in the US. We assessed hepatitis vaccination series completion rates among 350,240 commercial/Medicare 12,599 Medicaid enrollees aged ≥19 years. was considered as completed provided that minimum interval between doses, defined by CDC, number of doses were reached. stratified vaccine type (i.e. monovalent or bivalent) at initial for each cohort. In cohort, rate 32.0% 39.6% those who initiated with a vaccine, it 36.2% 48.9% bivalent vaccine. 21.0%...
Herpes zoster (HZ) is a painful dermatomal rash caused by reactivation of latent varicella-zoster virus. The incidence HZ increased for immunocompromised (IC) individuals. objective this study to assess the healthcare costs incurred IC individuals who develop with or without associated complications. We conducted retrospective case-control across US over 5-year period, based on health insurance claims data aged ≥50 years identified as disease immunosuppressive treatment. A cohort 30,107...
Patients with chronic obstructive pulmonary disease (COPD) are potentially at increased risk of herpes zoster (HZ). Little is known about the impact an HZ episode on health care resource utilization (HRU) and costs among patients COPD.This retrospective cohort study individuals aged ≥50 years in United States (US) used administrative claims data from Optum's de-identified Clinformatics Data Mart Database for commercially insured Medicare Advantage members (2013-2018). Two cohorts COPD,...